Back to Search
Start Over
In Vitro Susceptibility of Burkholderia cepacia Complex Isolated from Cystic Fibrosis Patients to Ceftazidime-Avibactam and Ceftolozane-Tazobactam.
- Source :
-
Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2018 Aug 27; Vol. 62 (9). Date of Electronic Publication: 2018 Aug 27 (Print Publication: 2018). - Publication Year :
- 2018
-
Abstract
- We tested the in vitro susceptibility of ceftazidime-avibactam and ceftolozane-tazobactam and 13 other antibiotics against 91 Burkholderia cepacia complex (BCC) strains isolated from cystic fibrosis patients since 2012. The highest susceptibility (82%) was found for trimethoprim-sulfamethoxazole. Eighty-one and 63% of all BCC strains were susceptible to ceftazidime-avibactam and ceftolozane-tazobactam, respectively. For temocillin, ceftazidime, piperacillin-tazobactam, and meropenem, at least 50% of the strains were susceptible. B. stabilis seems to be more resistant than other BCC species.<br /> (Copyright © 2018 American Society for Microbiology.)
- Subjects :
- Anti-Bacterial Agents pharmacology
Burkholderia cepacia complex isolation & purification
Drug Combinations
Humans
Microbial Sensitivity Tests
Sulfamethoxazole pharmacology
Tazobactam pharmacology
Trimethoprim pharmacology
Azabicyclo Compounds pharmacology
Burkholderia cepacia complex drug effects
Ceftazidime pharmacology
Cephalosporins pharmacology
Cystic Fibrosis microbiology
Tazobactam pharmacokinetics
Subjects
Details
- Language :
- English
- ISSN :
- 1098-6596
- Volume :
- 62
- Issue :
- 9
- Database :
- MEDLINE
- Journal :
- Antimicrobial agents and chemotherapy
- Publication Type :
- Academic Journal
- Accession number :
- 29914964
- Full Text :
- https://doi.org/10.1128/AAC.00590-18